1. From the Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California-San Francisco/Mt. Zion Comprehensive Cancer Center, University of California (MRC, DPL, PRC, CJK) and Veterans Affairs Medical Center (CJK), San Francisco, California, Veterans Affairs Puget Sound Health Care System (DFP) and Department of Urology, University of Washington (DFP), Seattle, Washington, and TAP Pharmaceutical Products, Inc., (SSM), Lake Forest, Illinois